Empagliflozin reduces the senescence of cardiac stromal cells and improves cardiac function in a murine model of diabetes

The sodium‐glucose cotransporter 2 (SGLT2) inhibitor empagliflozin reduces heart failure in diabetes, but underlying mechanisms remain elusive. We hypothesized that empagliflozin could counteract the senescence of cardiac stromal cells (CSC), the action of which limits cardiac damage and cardiac fib...

Descripción completa

Detalles Bibliográficos
Autores principales: Madonna, Rosalinda, Doria, Vanessa, Minnucci, Ilaria, Pucci, Angela, Pierdomenico, Donato Sante, De Caterina, Raffaele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687009/
https://www.ncbi.nlm.nih.gov/pubmed/32940423
http://dx.doi.org/10.1111/jcmm.15699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7687009/
https://www.ncbi.nlm.nih.gov/pubmed/32940423
http://dx.doi.org/10.1111/jcmm.15699

Ejemplares similares